First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022.

Brussels (Belgium), 23 May 2022 – UCB, a global pharmaceutical company, today announced new 24-week data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, evaluating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) and active ankylosing spondylitis (AS). [i] , [ii] Both studies met their primary and all ranked secondary endpoints at week 16, with statistical significance, demonstrating improvements versus placebo in the signs and symptoms of disease across the full spectrum of axSpA with consistent outcomes for patients with nr-axSpA and patients...